Equity Research

Should You Buy OFS Credit Company, Inc. - 7.87 Stock in 2026?

By CirclFi Research Team · · 4/13 models active

According to the CirclFi Deep Alpha Valuation Engine, OFS Credit Company, Inc. - 7.87 (OCCIM) sits in the bottom tier of our quality coverage with a score of 1.9/10. While a weak quality score suggests operational challenges, our valuation models assess if the market has over-discounted the stock at $25.09.

The short answer: 3 of 4 CirclFi valuation models project upside for OFS Credit Company, Inc. - 7.87 (OCCIM) at $25.09 — the model consensus leans bullish, with a Quality Score of 1.9/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 3 of 4 models see upside — majority bullish
  • Quality Score: 1.9/10 — Very Weak — significant concerns
  • Value Trap Risk: —/100 — Not scored
  • Fair Value Range: $20.29 – $144.83 (614% spread)

Bullish Models

3 / 4

Bearish Models

1 / 4

Quality Score

1.9 /10

Very Weak — significant concerns

Value Trap Risk

/100
Not scored

Not scored

Model Consensus

4 /13
Active Models

Avg. confidence: 3%

Investment Thesis

The Bull Case

Target: $144.83 (+477.2% upside)

  • According to the CirclFi Deep Alpha Valuation Engine, 3 of 4 models identify upside from $25.09 to a composite fair value of $83.58, indicating the market hasn't fully priced in OFS Credit Company, Inc. - 7.87's earnings power.
  • According to the CirclFi Deep Alpha Valuation Engine, the CUCE model targets a fair value of $144.83 (+477.2%), anchoring the bull case with a methodology that provides a differentiated analytical lens.

The Bear Case

Target: $20.29 (-19.1%)

  • According to the CirclFi Quality of Company (QOC) framework, OFS Credit Company, Inc. - 7.87's rating of 1.9/10 indicates below-average quality, raising questions about sustainable earnings levels.
  • According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model sees the stock as overvalued with a fair value of $20.29 (-19.1%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +496.4% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

Peer Benchmarking

PSEC Prospect Capital Cor
8.4
SCM Stellus Capital Inve
7.8
FDUS Fidus Investment Cor
7.6
HTGC Hercules Capital, In
7.6
GLAD Gladstone Capital Co
7.4

Valuation Divergence

Spread

614%

Fair Value Range

$20.29 – $144.83

A 614% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

CUCE

$144.83 (+477.2%)

Most Bearish

Markov DDM

$20.29 (-19.1%)

Key Risk Factors

Weak Fundamentals

QOC 1.9/10 signals below-average quality.

Model Disagreement

614% spread signals high variance in projections.

Macro/Sector Risk

— headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View OCCIM Data Page →

The Bottom Line

OFS Credit Company, Inc. - 7.87 at $25.09 presents what our engine identifies as a high-conviction opportunity: 3 of 4 models see upside, quality stands at 1.9/10, and the composite fair value of $83.58 implies +233.1% return potential. Investors should verify this thesis against their own risk parameters and time horizon.

These are quantitative model outputs, not investment recommendations. OFS Credit Company, Inc. - 7.87's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy OCCIM stock right now?

Based on CirclFi's multi-model analysis, 3 of 4 models see upside for OCCIM at $25.09. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 1.9/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in OFS Credit Company, Inc. - 7.87?

Key risks include: a below-average Quality Score of 1.9/10, indicating fundamental weakness; limited model coverage (4/13 active), reducing analytical confidence; wide model disagreement (614% spread), signaling high uncertainty; general market and sector-specific risks affecting — companies. Always diversify and consult a financial advisor.

How does OCCIM compare to its competitors?

Among — peers, OCCIM holds a Quality Score of 1.9/10. Comparable companies include PSEC (QOC 8.4), SCM (QOC 7.8), FDUS (QOC 7.6). The relative ranking helps investors identify whether OCCIM offers better fundamental quality than alternatives in the same sector.

Is OCCIM a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. OCCIM's Quality Score of 1.9/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy OCCIM at?

CirclFi does not provide target buy prices or price alerts. However, our 4 active models produce fair value estimates ranging from $20.29 to $144.83. At $25.09, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for OCCIM.

View OCCIM Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →